20
Participants
Start Date
June 12, 2018
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2026
Nivolumab
Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
Columbia University Medical Center, New York
Weill Cornell Medical College, New York
Miami Cancer Center, Miami
Dana Farber Cancer Institute, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Fabio Iwamoto, MD
OTHER